STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Clinical trials for STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 trials appear
Sign up with your email to follow new studies for STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial tests ipilimumab against standard therapy for High-Risk melanoma
Disease control OngoingThis phase 3 trial tests whether the immunotherapy drug ipilimumab is better than high-dose interferon alfa-2b at preventing melanoma from coming back in patients whose cancer was removed by surgery. Over 1,600 people with high-risk stage III or IV melanoma took part. The study m…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
Immune cocktail shows promise for Tough-to-Treat melanoma
Disease control OngoingThis phase II trial tests whether adding a growth factor (GM-CSF) to the immunotherapy drug ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that cannot be surgically removed are randomly assigned to get ipilimumab alone…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
Could a third drug boost melanoma immunotherapy?
Disease control OngoingThis study tests whether adding a drug called sargramostim to the standard immunotherapy combination of nivolumab and ipilimumab helps people with advanced melanoma live longer. About 600 patients with stage III or IV melanoma that cannot be surgically removed are participating. …
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
Could taking a break from melanoma drugs be just as good?
Disease control OngoingThis phase 2 trial compares two ways of taking the targeted drugs dabrafenib and trametinib for advanced BRAF-mutant melanoma: continuously versus with planned breaks. About 280 people with stage III or IV melanoma that cannot be surgically removed are participating. The goal is …
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Triple threat: new combo therapy targets Hard-to-Treat melanoma
Disease control OngoingThis phase II trial is testing two different three-drug combinations in people with advanced BRAF-mutated melanoma that has spread or cannot be removed by surgery. One group receives nivolumab (immunotherapy) plus dabrafenib and trametinib (targeted therapy); the other receives n…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental drug dinaciclib tested in advanced melanoma patients
Disease control OngoingThis phase II trial is testing the drug dinaciclib in 72 people with stage IV melanoma that has spread. The drug works by blocking enzymes that help cancer cells grow. Researchers are looking at side effects and whether it helps patients live longer or slows tumor growth.
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Double immune attack: new combo therapy shows promise for tough melanoma
Disease control OngoingThis study tested two different doses of the immunotherapy drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be surgically removed. The goal was to see if the combination could delay cancer growth better than i…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy offers hope for melanoma patients who failed standard treatment
Disease control OngoingThis phase 2 trial studies a combination of two immunotherapy drugs—talimogene laherparepvec (T-VEC) and pembrolizumab—in 43 adults with advanced melanoma that has worsened despite prior anti-PD1/L1 therapy. T-VEC is a modified virus that infects and kills cancer cells while also…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a cancer drug slow down advanced melanoma? small trial hopes to find out
Disease control OngoingThis phase 2 trial is testing the drug ibrutinib in 18 people with stage IV melanoma that has not responded to previous treatments. Ibrutinib works by blocking certain enzymes that help cancer cells grow. The study aims to see if the drug can shrink tumors and how long it keeps t…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Breathing in a cancer fighter: inhaled IL-2 trial targets lung tumors
Disease control OngoingThis study tests an inhaled form of interleukin-2 (IL-2), a protein that boosts the immune system, in people whose cancer has spread to the lungs. The goal is to find the best dose and see if it can shrink lung tumors. About 70 adults with cancers like melanoma, sarcoma, or kidne…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Supercharged T-Cells take on melanoma in early trial
Disease control OngoingThis early-phase trial tests whether giving patients with advanced melanoma immune cells that have been genetically modified to resist tumor-suppressing signals can help fight the cancer. The modified T-cells are given along with high-dose Interleukin-2, a drug that boosts immune…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Drug combo aims to starve and block cancer in early trial
Disease control OngoingThis early-phase trial tested two oral drugs, cediranib and selumetinib, in 19 people with advanced solid tumors (including melanoma) that had stopped responding to standard treatments. Cediranib works by cutting off blood supply to tumors, while selumetinib blocks a key growth s…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a malaria drug help fight cancer? early trial tests new combo
Disease control OngoingThis early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug combo aims to boost immune attack on melanoma
Disease control OngoingThis early-phase trial is testing whether combining two drugs—pembrolizumab (Keytruda) and ibrutinib (Imbruvica)—can safely treat advanced melanoma that cannot be removed by surgery. Pembrolizumab helps the immune system fight cancer, while ibrutinib blocks enzymes that help canc…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC